Saroglitazar and vitamin E vs. lifestyle interventions in metabolic dysfunction associated steatotic liver disease: A 3-arm randomised study.
- 2026-05-16
- RCT · n = 136
- The Indian journal of medical research 163
- Anurag Kumar Tiwari
- Gurvachan Singh
- Vinod Kumar
- Dawesh Prakash Yadav
- Sunit Kumar Shukla
- Virendra Singh
- Gaurav Mishra
- Narendra Kumar Tiwary
- Anand Anunay
- Divyanshi Singh
- Deepika Chaturvedi
- PubMed: 42237829
- DOI: 10.25259/ijmr_2511_2025
- High evidence
- Large Human Trial
- Clinical
The changes from baseline were not-significant for NAFLD fibrosis score [0.05±0.52, 0.06±0.64 and -0.12±1.0, 95% confidence interval (CI), P =0.41]
- Effect
- Neutral
- Effect size
- Small
- Significant
- No
- Dose
- not specified in abstract